5077472026-04-012026-06-305077472026-06-305077472026-04-012026-06-30in-capmkt:OtherExpenses1Member5077472026-04-012026-06-30in-capmkt:ReportableSegments1Member5077472026-04-012026-06-30in-capmkt:ReportableSegments2Member5077472026-04-012026-06-30in-capmkt:ReportableSegments3Member5077472026-04-012026-06-30in-capmkt:ReportableSegments4Member5077472026-04-012026-06-30in-capmkt:ReportableSegments5Member5077472026-04-012026-06-30in-capmkt:ReportableSegments6Member5077472026-04-012026-06-30in-capmkt:ReportableSegments1Member5077472026-04-012026-06-30in-capmkt:ReportableSegments2Member5077472026-04-012026-06-30in-capmkt:ReportableSegments3Member5077472026-04-012026-06-30in-capmkt:ReportableSegments4Member5077472026-04-012026-06-30in-capmkt:ReportableSegments5Member5077472026-04-012026-06-30in-capmkt:ReportableSegments6Member5077472026-04-012026-06-30in-capmkt:ReportableSegments1Member5077472026-06-30in-capmkt:ReportableSegments1Member5077472026-04-012026-06-30in-capmkt:ReportableSegments2Member5077472026-06-30in-capmkt:ReportableSegments2Member5077472026-04-012026-06-30in-capmkt:ReportableSegments3Member5077472026-06-30in-capmkt:ReportableSegments3Member5077472026-04-012026-06-30in-capmkt:ReportableSegments4Member5077472026-06-30in-capmkt:ReportableSegments4Member5077472026-04-012026-06-30in-capmkt:ReportableSegments5Member5077472026-06-30in-capmkt:ReportableSegments5Member5077472026-04-012026-06-30in-capmkt:ReportableSegments6Member5077472026-06-30in-capmkt:ReportableSegments6Member5077472026-04-012026-06-30in-capmkt:ReportableSegments1Member5077472026-06-30in-capmkt:ReportableSegments1Member5077472026-04-012026-06-30in-capmkt:ReportableSegments2Member5077472026-06-30in-capmkt:ReportableSegments2Member5077472026-04-012026-06-30in-capmkt:ReportableSegments3Member5077472026-06-30in-capmkt:ReportableSegments3Member5077472026-04-012026-06-30in-capmkt:ReportableSegments4Member5077472026-06-30in-capmkt:ReportableSegments4Member5077472026-04-012026-06-30in-capmkt:ReportableSegments5Member5077472026-06-30in-capmkt:ReportableSegments5Member5077472026-04-012026-06-30in-capmkt:ReportableSegments6Member5077472026-06-30in-capmkt:ReportableSegments6Member5077472026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares507747TTKHLTCARENOTLISTEDINE910C01018TTK HEALTHCARE LIMITEDMain BoardEquity2026-04-012027-03-312026-08-062026-07-27INRLakhsQuarterlyFirst quarterMulti segment2026-08-0612:00:002026-08-0613:00:00Not applicablefalsefalseNot Applicable2026-04-012026-06-30UnauditedStandalone25755760001679470002743523000612325000551327000-217340004661270005312000214050008201780002454940000288583000028858300076000000-2090007579100002127920000000212792000335230002463150001413030001015.0615.060015.0615.06Notes: <br /> (1) The above financial results for the First Quarter ended June 30, 2026 in respect of TTK Healthcare Limited (the Company) have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 06, 2026 at the Registered Office of the Company, also with the provision of Video Conferencing facility. <br /> (2) The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> (3) During the Fourth Quarter of FY 2024-25, the Company had written off the entire value of Male Contraceptives pertaining to Protective Devices Division amounting to Rs.586.39 lakhs that were meant for export under USAID Program, owing to 90-day pause on foreign development assistance and subsequent cancellation of Purchase Orders. This write off was shown as Exceptional Item during FY 2024-25. <br /> In the First Quarter of this financial year, the Company has received orders for inventory amounting to Rs.544.63 lakhs, which were written off in FY 2024-25. Out of the order for Rs.544.63 lakhs, the Company has invoiced in First Quarter of this year, inventory amounting to Rs.509.92 lakhs for a selling value of Rs.701.85 lakhs to USAID, which is included in the revenue for the quarter. <br /> (4) Exceptional Items pertaining to the previous year: <br /> (a) On November 21, 2025, the Government of India notified the four Labour Codes, consolidating 29 existing labour laws, and the Ministry of Labour & Employment subsequently issued draft Central Rules and FAQs. Based on the best information available and in line with the guidance issued by the Institute of Chartered Accountants of India, the Company had assessed the incremental impact arising from the change in the definition of wages and, considering its material, regulatory-driven and non-recurring nature, had presented the same as Exceptional items in the Statement of Profit and Loss for the previous year ended March 31, 2026. <br /> The incremental impact comprised Gratuity of Rs.823.02 lakhs and Long-term Compensated Absences of Rs.284.85 lakhs, against which the provision of Rs.350 lakhs created in FY 2020–21 was adjusted, resulting in a net charge of Rs.757.87 lakhs being recognised in the previous financial year. <br /> (b) The Company had recognised Rs.350.42 lakhs as Exceptional Income during the previous financial year towards GST refund relating to earlier periods, which was received subsequently. <br /> (5) The Company has entered into definitive agreements with M/s. Wipro Enterprises Private Limited on July 23, 2026, for the sale of EVA and Good Home Brands and related assets, for a consideration of Rs.256 crores plus applicable GST, pursuant to approval by the Board of Directors on that date. The net book value of the related assets was Rs.70.48 lakhs as at June 30, 2026. Since the said transaction is expected to be completed by September 30, 2026, the impact of the same shall be given effect to in the Quarter in which it is completed. <br /> (6) The tax relating to earlier years mentioned in the previous year represents the tax refund relating to AY 2016-17 & AY 2017-18 received, consequent to completion of assessments. <br /> (7) The Company does not have any Subsidiary / Associate / Joint Venture Company(ies) as on June 30, 2026. <br /> (8) The figures for the Quarter ended March 31, 2026 are the balancing figures between the Audited Figures in respect of the full financial year and the published year to date figures upto the end of the Third Quarter of the relevant financial year which were subjected to Limited Review. <br /> (9) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. <br /> (10) The full financial results for the First Quarter ended June 30, 2026 are available on the website of BSE Limited (www.bseindia.com), National Stock Exchange of India Limited (www.nseindia.com) and also on the website of the Company (www.ttkhealthcare.com). Other Expenses820178000Animal Welfare358950000Consumer Products770346000Medical Devices335933000Protective Devices726906000Foods382222000Others1219000257557600002575576000Animal Welfare11513000Consumer Products28444000Medical Devices75802000Protective Devices61320000Foods41232000Others10840002193950005312000-74500000288583000Animal Welfare440898000Consumer Products563883000Medical Devices940123000Protective Devices1605363000Foods556448000Others303010004137016000976226800013899284000Animal Welfare311500000Consumer Products683760000Medical Devices190320000Protective Devices498005000Foods157773000Others1346400018548220006496440002504466000Notes: <br /> (1) Segments have been identified in line with the Indian Accounting Standard on Segment Reporting (Ind AS 108) based on review of performance by the Top Management. <br /> (2) Details of products included in each of the Segments are as below : <br /> (i) Animal Welfare comprise products for Veterinary use. <br /> (ii) Consumer Products comprise marketing and distribution of Woodward's Gripewater, EVA Range of Cosmetics, Good Home Range of Scrubbers, Air Fresheners, etc. <br /> (iii) Medical Devices include Artificial Heart Valves, Orthopaedic Implants, etc. <br /> (iv) Protective Devices comprise manufacturing and marketing of Male Contraceptives and other allied products. <br /> (v) Foods comprise manufacturing and marketing of Food Products. <br /> v "Others" include Printing and Publishing of Maps and Atlases. <br /> (3) The Segment wise revenue, results, assets and liabilities figures relate to respective amounts directly identifiable to each of the segments. The unallocable expenditure includes expenses incurred on common services at the corporate level and also those expenses not identifiable to any specific segment. <br /> (4) The previous period's / year's figures have been regrouped and reclassified, wherever necessary to conform to the current period's / year's presentation. Items that will not be reclassified subsequently to profit or loss3459900034599000107600033523000